AIM Stock Summary and Trading Ideas (Aim Immunotech | AMEX:AIM)

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Aim Immunotech trades on the AMEX stock market under the symbol AIM.

As of January 7, 2025, AIM stock price was flat at $0.25 with 347,454 million shares trading.

AIM has a beta of 1.42, meaning it tends to be more sensitive to market movements. AIM has a correlation of 0.06 to the broad based SPY ETF.

AIM has a market cap of $15.94 million. This is considered a Sub-Micro Cap stock.

Last quarter Aim Immunotech reported $35,000 in Revenue and -$.06 earnings per share. This beat revenue expectation by $23,330 and exceeded earnings estimates by $.03.

In the last 3 years, AIM traded as high as $1.38 and as low as $.16.

The top ETF exchange traded funds that AIM belongs to (by Net Assets): VTI, VXF.

AIM has underperformed the market in the last year with a return of -43.2%, while the SPY ETF gained +29.0%. In the last 3 month period, AIM fell short of the market, returning -5.1%, while SPY returned +4.5%. However, in the most recent 2 weeks AIM has outperformed the stock market by returning +33.3%, while SPY returned +0.3%.

AIM support price is $.23 and resistance is $.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AIM shares will trade within this expected range on the day.